stockrowKiniksa Pharmaceuticals International, plc
KNSA Healthcare Drug Manufacturers Specialty & Generic
Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.
- Revenue
- +58.1%
- EPS
- +142.2%
- Free cash flow
- +43.5%
Quarter to September 2026, against a year earlier
Follow KNSA
Alert me
Kiniksa Pharmaceuticals International, plc (KNSA) Price to free cash flow
As of 5 November 2026, Kiniksa Pharmaceuticals International, plc (KNSA) trades at a price to free cash flow of 35.1×. Over the past ten years it has ranged from 0.0× (December 2023) to 194× (January 2023); the current reading is higher than 78% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 16.3× and above the Healthcare sector median of 21.1×.
Price to free cash flow, daily
Embed this chart
Annual newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2025 | 22.4× | (59.48%) |
| FY2024 | 55.3× | (43.46%) |
| FY2023 | 97.9× | (44.96%) |
| FY2022 | 178× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| Sep 2026 | 29.6× | 9.03% |
| Jun 2026 | 27.1× | 20.96% |
| Mar 2026 | 22.4× | 0.00% |
| Dec 2025 | 22.4× | (21.30%) |
| 18 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | n/m |
| LNTH Lantheus Holdings, Inc. compare | 16.9× |
| LQDA Liquidia Corporation compare | 26.4× |
| ALKS Alkermes plc compare | 32.8× |
| ELAN Elanco Animal Health Incorporated compare | 33.2× |
| KNSA Kiniksa Pharmaceuticals International, plc | 35.1× |
| HIMS Hims & Hers Health, Inc. compare | 67.3× |
| SUPN Indivior Pharmaceuticals Inc. compare | 115× |
| RDY Dr. Reddy's Laboratories Ltd compare | 126× |
| Drug Manufacturers Specialty & Generic industry median | 16.3× |
| Healthcare sector median | 21.1× |
| Market median | 14.1× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on KNSA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement